132 related articles for article (PubMed ID: 2576207)
1. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
Brandt-Rauf PW; Pincus MR; Chen JM
J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
[TBL] [Abstract][Full Text] [Related]
2. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
Brandt-Rauf PW; Rackovsky S; Pincus MR
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
[TBL] [Abstract][Full Text] [Related]
3. Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states.
Brandt-Rauf PW; Pincus MR; Monaco R
J Protein Chem; 1995 Jan; 14(1):33-40. PubMed ID: 7779261
[TBL] [Abstract][Full Text] [Related]
4. Conformation of the transmembrane domain of the epidermal growth factor receptor.
Brandt-Rauf PW; Monaco R; Pincus MR
J Protein Chem; 1994 Feb; 13(2):227-31. PubMed ID: 7914727
[TBL] [Abstract][Full Text] [Related]
5. Influence of a mutation in the transmembrane domain of the p185c-erbB2 oncogene-encoded protein studied by molecular dynamics simulations.
Garnier N; Genest D; Hebert E; Genest M
J Biomol Struct Dyn; 1994 Apr; 11(5):983-1002. PubMed ID: 7946067
[TBL] [Abstract][Full Text] [Related]
6. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers.
Sharpe S; Barber KR; Grant CW
Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974
[TBL] [Abstract][Full Text] [Related]
7. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.
Bargmann CI; Hung MC; Weinberg RA
Cell; 1986 Jun; 45(5):649-57. PubMed ID: 2871941
[TBL] [Abstract][Full Text] [Related]
8. A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H; Bangalore L; Bormann BJ; Stern DF
EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
10. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
Sajot N; Genest M
J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
[TBL] [Abstract][Full Text] [Related]
11. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
Bargmann CI; Weinberg RA
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
[TBL] [Abstract][Full Text] [Related]
12. An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change.
Brandt-Rauf PW; Bomzer G; Belford D; Pincus MR
J Protein Chem; 1991 Aug; 10(4):437-41. PubMed ID: 1838257
[TBL] [Abstract][Full Text] [Related]
13. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
[TBL] [Abstract][Full Text] [Related]
14. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.
Gullick WJ; Bottomley AC; Lofts FJ; Doak DG; Mulvey D; Newman R; Crumpton MJ; Sternberg MJ; Campbell ID
EMBO J; 1992 Jan; 11(1):43-8. PubMed ID: 1346763
[TBL] [Abstract][Full Text] [Related]
15. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.
Chen LI; Webster MK; Meyer AN; Donoghue DJ
J Cell Biol; 1997 May; 137(3):619-31. PubMed ID: 9151669
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann CI; Weinberg RA
EMBO J; 1988 Jul; 7(7):2043-52. PubMed ID: 2901345
[TBL] [Abstract][Full Text] [Related]
17. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Stern DF; Kamps MP; Cao H
Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
[TBL] [Abstract][Full Text] [Related]
19. Conformational effects of amino acid substitutions at positions 10, 12, and 13 in the P21 protein.
Brandt-Rauf PW; Pincus MR; Carty RP; Lubowsky J; Avitable M; Kung HF; Maizel J
J Protein Chem; 1989 Feb; 8(1):79-86. PubMed ID: 2669815
[TBL] [Abstract][Full Text] [Related]
20. Structural implications of a Val-->Glu mutation in transmembrane peptides from the EGF receptor.
Sharpe S; Grant CW; Barber KR; Giusti J; Morrow MR
Biophys J; 2001 Dec; 81(6):3231-9. PubMed ID: 11720988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
